subscribeSubscribe
HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA

HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA
GLOBENEWSWIRE
12 Dec 2023
Share Share
FDA rejects two China-developed cancer drugs

FDA rejects two China-developed cancer drugs
J. Gardner BIOPHARMADIVE
03 May 2022
Share Share
Hutchmed announces agreement with NHSA for adding oncology drugs Elunat

Hutchmed announces agreement with NHSA for adding oncology drugs Elunat
PHARMABIZ
06 Dec 2021
Share Share
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA & TUOYI

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA & TUOYI
GLOBENEWSWIRE
20 Sep 2021
Share Share
USFDA Accepts Filing of HUTCHMED’s NDA for Surufatinib

USFDA Accepts Filing of HUTCHMED’s NDA for Surufatinib
GLOBENEWSWIRE
01 Jul 2021
Share Share
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda in China)

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda in China)
GLOBENEWSWIRE
18 Jun 2021
Share Share
China NMPA approves Chi-Med’s surufatinib

China NMPA approves Chi-Med’s surufatinib
PHARMABIZ
01 Jan 2021
Share Share
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China)

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China)
PRESS RELEASE
30 Dec 2020
Share Share
Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors

Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors
ONCLIVE
28 Dec 2020
Share Share
Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors

Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors
ONCLIVE
28 Dec 2020
Share Share